Accessibility Policy

Statement of Commitment

CPDC is committed to treating all people in a way that allows them to maintain their dignity and independence through integration and equal opportunity. We are committed to meeting the needs of people with disabilities in a timely manner, and will do so by preventing and removing barriers to accessibility and meeting accessibility requirements under the Accessibility for Ontarians with Disabilities Act, 2005.

Training

CPDC will provide training to employees and other relevant persons. Training will be provided in a way that best suits the duties of these identified groups.

CPDC will take the following steps to ensure employees are provided with the training required to meet Ontario’s accessible laws by January 1, 2015:

  • Current employees will be trained on all appropriate policies, practices, and procedures that affect the way in which goods and services are provided to persons with disabilities. This will include how to interact with people with disabilities using an assistive device or requiring the assistance of a service animal or support person.
  • New employees will receive accessibility training as part of Orientation.
  • Employees will be re-trained when changes are made to CPDC’s Accessibility policies, practices, and procedures.
  • Completed training sign off forms will be kept in employee training files.

Information and Communications

CPDC is committed to meeting the communication needs of people with disabilities. We will ensure that proper consideration is provided to employees, customers, and candidates with regard to determining their information and communication needs. We will ensure that all publicly available information is accessible upon request.

  • Emergency Information – CPDC is committed to providing customers, vendors, and partners with publicly available emergency information in an accessible format upon request.
  • Feedback/Requests – Feedback or other requests for accommodation can be directed as follows:

Human Resources
Centre for Probe Development and Commercialization
1280 Main Street West, NRB-A316
Hamilton, ON L8S 4K1
Phone: 905 525-9140 x21112
Fax: 905 522-7776
hr@imagingprobes.ca

Employment

  • Employees – CPDC ensures that employees with disabilities are provided with necessary assistance during emergencies. Emergency response information will be reviewed when changes are made to the employee’s work location.
  • Recruitment, Assessment, and Hiring – Candidates with disabilities will be accommodated during the recruitment, assessment, and hiring process by January 1, 2016.
  • Individual Accommodation Plans/Return-to-Work Policies – By January 1, 2016, CPDC will put in place a plan to develop individual accommodation plans and return-to-work policies for employees who have been absent due to a disability.
  • Performance Management, Career Development, and Redeployment Processes – The Performance Management and Professional Development policies will be reviewed and updated, as required, to ensure that the needs of disabled employees are taken into account by January 1, 2016.

Design of Public Spaces

CPDC commits to meeting Accessibility Standards for the Design of Public Spaces when building or making modifications to public spaces. We will notify the public of any service disruption, should they occur, and provide available alternatives.

Plan and Policy Review

CPDC supports the full inclusion of persons with disabilities as identified in Accessibility for Ontarians with Disabilities Act, 2005 (AODA). As such, all policies and procedures will be developed or updated so as to respect and promote the dignity and independence of persons with disabilities. As required, this plan will be reviewed and updated every 5 years.

CPDC In-Licenses Enabling Technology to Advance Effectiveness of Immunotherapy

The Centre for Probe Development and Commercialization (CPDC) at McMaster University in Hamilton, Ontario, announces that it has licensed the Centyrin® platform from Janssen Biotech, Inc. for exclusive use in combination with its radiopharmaceutical expertise to create novel nuclear imaging probes against immunotherapy drug targets. Immunotherapy has become one of the most active areas in

CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.

CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.

CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.

Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.

During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.

CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.

CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.

Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.

Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.

ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.